The 2026 Hemophilia Fellowship – United States, a competitive grant program from Pfizer, supports an institution-based fellowship emphasizing shared decision making (SDM), patient education, and multidisciplinary team-based care. The program aims to strengthen hemophilia care through equitable education and patient-centered shared decision making in a rapidly evolving treatment landscape.

Overview

The fellowship is designed for accredited U.S.-based academic institutions with established clinical training programs. Institutions are encouraged to identify and address educational needs, barriers, and gaps for People Living with Hemophilia (PLwH) relating to the new treatment landscape. A structured education program including care for underserved populations, an SDM training curriculum, mentorship, and a practical capstone project are strongly encouraged.

Funding and Benefits

Grant funding is available to support one fellow for up to one year at $100,000 USD. The budget may only include salary and support of the fellow benefits. Grant funds cannot be used for overhead or indirect costs. Funding will be awarded to the institution, not an individual.

Eligibility

Geographic Scope: United States

Applicant Eligibility Criteria:

• Accredited, US-based academic institution.
• Institutions with fellowship programs that include independent research and a strong mentoring program.
• The name of the potential fellow(s) must not be included in application materials.
• No aspect of the fellowship program can benefit Pfizer’s business or a Pfizer asset.

Fellow Requirements:

• Any fellow receiving grant funds must be a U.S. Worker (U.S. citizen, permanent resident, refugee, or asylee), or hold an appropriate non-immigrant visa status authorizing employment in the U.S.
• The selected fellow will be named in transparency reporting as a recipient of grant funding.

Application Process

Applications must be submitted via the CyberGrants portal at www.cybergrants.com/pfizer/GMGFellowship.

Submission Requirements:

• Complete all required sections of the online application.
• Upload the proposal using the required Proposal Template.
• For the question "Competitive Grant?" select "Yes".
• Select the following Primary Area of Interest: Genetics - Hemophilia - FEL.
• Select the following Competitive Grant Program Name: 2026 RD US Hemophilia Fellowship.

Proposals will be evaluated by an Expert Review Panel (ERP) based on fellowship goals, objectives, medical needs and population health, patient care experience, program criteria, mentoring, training opportunities, and resources.

Deadline and Timeline

• RFP Release Date: 01 April 2026
• Submission Deadline: 28 May 2026 (23:59 Eastern Standard Time)
• Anticipated Grant Award Notification: 17 July 2026
• Anticipated Project Start Date: August 2027 or earlier
• Anticipated Project End Date: August 2028 or earlier

Contact Information

Questions regarding this RFP should be directed in writing to the Grant Officer, Talita Honorato-Rzeszewicz, at talita.honorato-rzeszewicz@pfizer.com with the subject line "2026 RD US Hemophilia Fellowship".

For technical difficulties with the CyberGrants website, please use the "Technical Questions" link within the portal.